Banks Sonja 4

What Happened
Sonja Banks, a director of Fulcrum Therapeutics (FULC), received a grant of an option covering 32,000 shares on June 30, 2026. The Form 4 reports the derivative award at $0.00 (no cash exchanged at grant). This is a compensation award (not a purchase or sale).

Key Details

• Transaction date: June 30, 2026; Form 4 filed July 2, 2026 (appears filed within the typical 2-business-day window).
• Transaction type/code: Award/Grant (code A) — option (derivative). Amount: 32,000 shares; reported price $0.00 and total $0.
• Vesting: The option vests with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders after the grant, subject to continued service (per footnote).
• Shares owned after transaction: Not specified in the filing.
• No 10b5-1 plan, tax-withholding sale, or immediate exercise/sale reported.

Context
This is a routine director equity grant used for compensation. As an option, it carries value only if it vests and is later exercised when the stock has market value; it is not an immediate bullish purchase signal.